



Ger Brennan

Global Established Brands Commercial Lead

Ger oversees the global strategy and operations of Organon's established brands franchise of trusted and impactful medicines around the world. He has been responsible for stabilizing the business and driving its return to growth, increasing market adoption, and acquiring new brands to further augment Organon's offerings across therapeutic areas.

He joined Organon from MSD, where he served as the managing director of Ireland and head of the country's leadership team. Previously, he was the global brand lead for the immunology franchise, driving the development of the strategy and overseeing the execution and the business performance of major products across all markets. He also served as immunology regional marketing lead for Mid-Europe and executive director for commercial operations in Europe and Canada, with responsibility for the development of commercial capabilities across the region.

Ger is a registered nurse in intellectual disability from the Daughters of Charity, Ireland.

About Organon Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women's health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon's existing products produce strong cash flows that support investments in innovation and future growth opportunities in women's health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, X and Facebook.